Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,696.21 -12.27 (-0.02%) CMC Crypto 200
1,424.13 -4.44 (-0.31%)
CRNX Sep 2024 40.000 call
| Previous close | 14.40 |
| Open | 14.40 |
| Bid | 6.20 |
| Ask | 10.50 |
| Strike | 40.00 |
| Expiry date | 2024-09-20 |
| Day's range | 14.40 - 14.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 53 |
Simply Wall St.Shareholders Will Probably Not Have Any Issues With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Key Insights Crinetics Pharmaceuticals will host its Annual General Meeting on 7th of June CEO R. Struthers' total...
GuruFocus.comInsider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...
On May 28, 2024, Stephen Betz, Chief Scientific Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), sold 3,000 shares of the company at a price of $47.49 per share.
GlobeNewswireCrinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs. “Dr. Cuddihy’s wealth of knowledge and experience both as a practicing physician in endocrinology and workin
